Navigation Links
Multiple Myeloma Therapeutics Future Discussed in In-demand MP Advisors Report Published at MarketPublishers.com
Date:10/1/2013

London,UK (PRWEB) October 01, 2013

Targeting unmet needs in treating hematological malignances through the development of innovative drugs has witnessed considerable achievements recently. Over the past 10 years, proteasome inhibitor Velcade (Bortezomib) and the immunomodulatory drugs such as Revlimid (lenalidomide) and Thalomid (thalidomide) have become the basic treatments for multiple myeloma (MM) leading to the improvement in survival rates. Nevertheless, new treatment options for relapsed/refractory multiple myeloma (RRMM) are required to further improve survival and the quality of life of this group patients, and new drugs, such as Kyprolis (carfilzomib) or Pomalyst (pomalidomide, Imnovid), have already started to successfully fulfill this need.

The ever increasing need for innovative therapies for unmet needs/challenging diseases spurs the pace of drug development, either directly or through partnership/in-licensing. Meantime, maturing pipeline, successful launches and new drug approvals sustain the growth trajectory of the biotech companies.

In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been recently published by Market Publishers Ltd.

Report Details:

Title: Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A
Published: September, 2013
Pages: 44
Price:    US$ 2,500.00
http://marketpublishers.com/report/diagnostics-diseases/cancer/treating-refractory-hematological-malignancies-multiple-myeloma-mm.html

The report offers an insightful overview of the therapies for multiple myeloma (including newly diagnosed – NDMM and relapsed/refractory – RRMM). It sheds light on the unmet needs and limitations of the current standard of care for relapsed and refractory MM patients. It describes the competitive scenario and delivers information on the leading biotech companies, covering clinical data of drugs, milestones, and valuation; indicates commercial opportunity in pursuing this therapy area. The research study reviews the early- and late-stage drugs in the clinic, covers key mergers and acquisitions in the area, provides clinical trial details of key drugs in pipeline, and offers an au-close look at the future of the drugs in the late-stage pipeline.

Report Scope:

  •     Comprehensive disease profile, review of unmet needs and description of the current standard of care.
  •     Extensive overview of the therapies for multiple myeloma (including newly diagnosed – NDMM and relapsed/refractory – RRMM).
  •     Data on the drugs in the pipeline: NDMM & RRMM – mechanism of action (MoA) and clinical stage of development.
  •     Clinical trial details of key drugs in pipeline.
  •     Discussion of the important issues related to the therapeutic area.
  •     Information on M&A and licensing deals that have taken place over the past five years.
  •     Evaluation of in-licensing and/or M&A opportunities.
  •     Insights into the competitive environment and detailed company profiles.
  •     Future outlook.

More new research reports by the publisher can be found at MP Advisors page.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11183653.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientists uncover multiple faces of deadly breast cancer
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Multiple thought channels may help brain avoid traffic jams
7. Study shows benefit of new maintenance therapy for multiple myeloma
8. FDA Issues Multiple Sclerosis Drug Alert
9. Pot Might Help Ease Multiple Sclerosis Symptoms
10. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
11. Multiple sclerosis patients have lower risk of cancer: UBC-VCH research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: